Hodgkin Lymphoma | Topics

Responses Observed in Entire Cohort of Patients With R/R CD30+ Hodgkin Lymphoma Receiving AFM13
April 15, 2021

In a phase 1 study of the innate cell engager AFM13, all 4 patients with CD30-positive, relapsed/refractory Hodgkin lymphoma treated with the therapy achieved at least a partial response.

Hope After Salvage Therapy Fails: Novel Agents for Relapsed/Refractory Hodgkin Lymphoma
May 14, 2019

In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.

Adding the T-Cell Booster Decitabine to Anti–PD-1 Therapy in Hodgkin Lymphoma
May 03, 2019

Researchers tested the addition of the T cell–boosting decitabine to anti–PD-1 therapy with camrelizumab among patients with relapsed or refractory classic Hodgkin lymphoma.